CD8A and hepatocellular carcinoma: To test the immunogenicity of the HCC-derived peptides, defined as their ability to induce peptide-specific CD8+ T cells, PBMCs from HD and HCC patients were weekly stimulated in vitro for 21–28 days with the irradiated and peptide-loaded PDC*line.